Skip to content

COOL-IT-PRO: Cryoablation of Breast Cancer in Non-surgical Patients

COOL-IT-PRO: Cryoablation of Breast Cancer in Non-surgical Patients: A Prospective Observational Registry

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05972343
Enrollment
100
Registered
2023-08-02
Start date
2023-07-26
Completion date
2031-07-31
Last updated
2026-05-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer, Cancer of the Breast

Brief summary

This is a subject registry study of patients who undergo cryoablation for their breast cancer after being determined not to be surgical candidates. Data collected as part of this registry will be used to assess the safety of percutaneous ultrasound-guided cryoablation in this population as well as provide long-term follow-up of subjects who received cryoablation.

Interventions

DEVICECryoablation

Takes place at single time point.

Sponsors

Washington University School of Medicine
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Eligibility Criteria: * Diagnosis of breast cancer. * Mass must be visible on ultrasound and \> 5 mm from skin. * Not undergoing surgery, because: * Patient has a medical condition that would not allow sedation or general anesthesia * Surgery is not clinically indicated due to unresectable and/or metastatic disease * Surgery is not clinically indicated for another reason * Patient declines surgery * At least 18 years old. * Able to understand and willing to sign an IRB-approved written informed consent document.

Design outcomes

Primary

MeasureTime frame
Proportion of patients who are free of serious treatment related complications per CTCAE v 5.0Through 3 year follow-up

Secondary

MeasureTime frame
Proportion of patients who demonstrate progression-free survival (PFS)At 3 year follow-up
Proportion of patients who demonstrate disease-free survival (DFS)At 3 year follow-up
Proportion of patients who demonstrate overall survival (OS)At 3 year follow-up

Countries

United States

Contacts

CONTACTHeather Garrett, M.D.
hvgarrett@wustl.edu314-454-5206
PRINCIPAL_INVESTIGATORHeather Garrett, M.D.

Washington University School of Medicine

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 8, 2026